Following several moderately sized venture funding rounds last month, Seattle tech companies in sectors like AI, biotech and data analytics are growing their products. Check out how these companies are fueling growth with a collective $256 million in new cash.
Top Seattle Tech Funding Rounds, September 2023
- Avalyn
- MotherDuck
- SkinnyDipped
- EchoMark
- Gable
#5. $7 million, September 13
Offering a platform that lets developers collaborate as they build and manage data assets, Gable pulled in a round of seed funding totaling $7 million. Zetta Venture Partners, Crane Venture Capital and Essence Venture Capital co-led the round that will help Gable fuel the development of its platform.
#4. $10 million, September 27
Headquartered in Kirkland, EchoMark offers an AI-powered information protection product that works to safeguard private communications like emails and documents. The company launched its solution with a $10 million seed investment led by Craft Ventures to expand its forensic watermarking technology across new workloads.
#3. $12 million, September 6
Foodtech company SkinnyDipped offers consumer snack products including flavored almonds, cashews and peanut butter cups. The brand’s products are free of artificial sweeteners, colors or flavors and are available through retailers across the country. The company’s Series A funding from lead investor David Grutman allows the company to expand into new retail stores like Costco and Publix.
#2. $52.5 million, September 20
Analytics company MotherDuck secured a Series B funding round led by Felicis. This latest infusion brings MotherDuck’s valuation to $400 million. The company’s solution is built in DuckDB, an open-source analytical processing database, and works to help businesses run analytics on their data. The company plans to grow its team by 15 people by the end of the year.
#1. $175 million, September 27
Biopharmaceutical company Avalyn works to develop targeted therapeutics to treat rare respiratory diseases. The company recently secured a round of Series C funding spearheaded by Perceptive Xontogeny Venture Funds, SR One and Eventide Asset Management to continue developing its portfolio of inhalation therapies for interstitial lung disease.
